Skip to content

Long-term of 10 Years Results of a Prospective Longitudinal Study

Usefulness of Home Blood Pressure Measurement in the Morning in Type 2 Diabetic Patients : Long-term (10 Years) Results of a Prospective Longitudinal Study

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01557972
Enrollment
400
Registered
2012-03-20
Start date
1999-11-30
Completion date
2013-03-31
Last updated
2012-03-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Blood Pressure, Type 2 Diabetes Mellitus

Brief summary

Previous cross-sectional studies have demonstrated that blood pressure (BP) measurements at home (HBP) in the morning offer stronger predictive power for micro- and macrovascular complications in patients with type 1 and 2 diabetes than casual/clinic blood pressure measurements (CBP) (Kamoi K et al, 2002-2003). Further, a prospective, longitudinal study for 6 years in patients with type 2 diabetes also demonstrated that control of wakening-up HBP provides the stronger predictive power for the outcomes than that of CBP did (Kamoi et al, 2010). However, it is not clear to show which of BP measurement provides the stronger predictive power for outcomes by comparing cumulative events over a longer time than 6 years. Therefore, the investigators examined which of HBP or CBP provides the stronger predictive power for outcomes in addition of renal anemia reported previously over 10 years in the patients with type 2 diabetes.

Interventions

PROCEDUREBlood pressure measurement based on HBP or CBP

To clarify which of HBP or CBP provides the stronger prediction power for the outcomes.

Sponsors

Nagaoka Red Cross Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
20 Years to 95 Years
Healthy volunteers
No

Inclusion criteria

* After a detailed baseline examination, 400 Japanese subjects with type 2 diabetes reported previously are followed up for all-cause mortality and morbidity.

Exclusion criteria

* Other than the above, patients judged inappropriate as the subjects of this study by the investigator

Design outcomes

Primary

MeasureTime frameDescription
DeathAverage time is 10 yearsNumber of participats not alive

Secondary

MeasureTime frame
Microvascular complications including renal anemiaAverage time is 10 years
Macrovascular complicationsAverage time is 10 years

Countries

Japan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026